Last updated: February 19, 2026
Disopyramide phosphate is an antiarrhythmic agent used primarily to treat ventricular arrhythmias. The API sourcing landscape involves global manufacturers, with specific points on regulatory compliance, manufacturing capacity, and quality standards.
Leading API Suppliers for Disopyramide Phosphate
The API market for disopyramide phosphate is limited due to its niche application and complex synthesis pathways. The primary API sources include:
| Supplier |
Location |
Manufacturing Capacity |
Regulatory Status |
Certification |
Quality Standards |
| Zhejiang Hisun Pharmaceuticals |
China |
Estimated at 10 metric tons/year |
FDA, EMEA compliance |
GMP certified |
USP, Ph. Eur. |
| Zhejiang Huahai Pharmaceutical |
China |
Estimated 8 metric tons/year |
GMP, FDA registrable |
GMP certified |
USP, Ph. Eur. |
| Jiangsu Hengrui Medicine Co. |
China |
Estimated 5 metric tons/year |
GMP, CNAS accreditation |
GMP certified |
USP, Ph. Eur. |
Regional focus remains on China due to lower manufacturing costs and established export infrastructure. Europe and India have limited suppliers of disopyramide phosphate API.
Manufacturing and Quality Considerations
The synthesis involves multi-step chemical processes with specific controls required for purity, residual solvents, and endotoxins:
- Key Synthesis Steps: N-alkylation of substituted aniline derivatives, followed by phosphate salt formation.
- Quality Criteria: Usually meet USP or Ph. Eur. specifications, including assay (95-105%), purity (>99%), and residual solvent limits.
Manufacturers maintain Good Manufacturing Practice (GMP) compliance, essential for API export to regulated markets like the U.S. and EU.
Regulatory and Commercial Trends
- Market Entry Barriers: Limited number of qualified manufacturers and complex synthesis routes.
- Regulatory Updates: API suppliers align with evolving GMP standards. Recent FDA inspections have focused on impurity profiles and batch consistency.
- Price Trends: API prices range from $200 to $400 per kilogram depending on volume, quality, and certification.
Sourcing Challenges and Risks
- Limited Supplier Pool: Only a few pharmaceutical-grade API manufacturers focus on disopyramide phosphate.
- Supply Chain Risks: Political instability, import restrictions, or quality issues can disrupt supply.
- Regulatory Delays: Changing GMP requirements or registration procedures can slow approval processes.
Outsourcing and Gridlock
- Contract manufacturing organizations (CMOs) in China and India serve as pivotal sources but require meticulous qualification processes.
- Pharmaceutical companies often engage multiple suppliers to mitigate risks associated with supply continuity and quality compliance.
Conclusion
Disopyramide phosphate API is few in number globally, with China dominating the supply chain. Key factors influencing sourcing include capacity, regulatory status, GMP compliance, and price stability. Buyers must evaluate suppliers on quality, reliability, and regulatory adherence for sustained supply.
Key Takeaways
- Chinese manufacturers dominate API supply for disopyramide phosphate.
- GMP compliance and regulatory approval are critical factors for API sourcing.
- Limited supplier pool increases supply chain risks.
- Price per kilogram varies significantly based on certification and volume.
- Quality standards align with USP and Ph. Eur. specifications.
Frequently Asked Questions
-
What are the primary regions supplying disopyramide phosphate API?
Mainly China, with small volumes from India and negligible presence in Europe.
-
Are there FDA-approved disopyramide phosphate API suppliers?
Yes, several Chinese manufacturers have FDA registration or are FDA-compliant, but actual approval depends on the specific manufacturer.
-
What are the typical quality standards for this API?
USP and Ph. Eur. standards are common, emphasizing assay, purity, residual solvents, and endotoxin limits.
-
How is the API synthesized?
The process involves N-alkylation reactions of precursor compounds, followed by phosphate salt formation under controlled conditions.
-
What are the main risks in sourcing disopyramide phosphate API?
Limited supplier options, potential regulatory delays, and supply chain disruptions pose significant risks.
Citations
[1] U.S. Pharmacopeia (USP). Disopyramide and its phosphate salt monograph. 2023.
[2] European Pharmacopoeia (Ph. Eur.). Disopyramide phosphate monograph. 2023.
[3] IMS Health. Global Pharmaceutical Market Data, 2022.
[4] FDA Drug Master Files and Inspection Reports, 2022.
[5] Chinese National Medical Product Administration (NMPA). GMP certification data, 2022.
